Eton Pharmaceuticals Files 8-K
Ticker: ETON · Form: 8-K · Filed: Apr 30, 2024 · CIK: 1710340
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: ETON
TL;DR
Eton Pharma filed an 8-K, but it's light on details for now.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on April 30, 2024, reporting other events and financial statements. The filing does not contain specific financial figures or details about the nature of the 'other events' beyond its classification.
Why It Matters
This 8-K filing indicates that Eton Pharmaceuticals has made a regulatory submission, but it lacks specific details on the events or financial information disclosed.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no immediate negative or positive financial implications disclosed.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- April 30, 2024 (date) — Date of report
FAQ
What specific 'Other Events' are being reported by Eton Pharmaceuticals?
The filing does not specify the nature of the 'Other Events' beyond the classification itself.
Are there any financial figures or updates included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but specific figures are not detailed in the provided text.
When was this 8-K filing submitted?
The filing was submitted on April 30, 2024.
What is Eton Pharmaceuticals' principal executive office address?
The principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is Eton Pharmaceuticals' IRS Employer Identification Number?
The IRS Employer Identification Number for Eton Pharmaceuticals is 37-1858472.
Filing Stats: 421 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-04-30 07:15:13
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20240426c_8k.htm (8-K) — 25KB
- ex_661653.htm (EX-99.1) — 9KB
- 0001437749-24-013838.txt ( ) — 166KB
- eton-20240430.xsd (EX-101.SCH) — 3KB
- eton-20240430_def.xml (EX-101.DEF) — 11KB
- eton-20240430_lab.xml (EX-101.LAB) — 15KB
- eton-20240430_pre.xml (EX-101.PRE) — 11KB
- eton20240426c_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On April 30, 2024, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ET-400, the Company's proprietary patented formulation of hydrocortisone oral solution. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated April 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 30, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4